1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the three months ended September 30, 2024, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
+Added: The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended March 31, 2025, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) (Rule 10b5-1 Plan), were as follows:
+Added: Rule 10b5-1 Trading Plan
+Added: Aggregate # of
+Added: Securities to be
+Added: Expiration Date
+Added: Purchase/Sale
+Added: Purchased/Sold
+Added: Curran Simpson
+Added: President and Chief Executive Officer
+Added: Other than as described above, during the three months ended March 31, 2025, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
Incorporated by Reference
1 unchanged sentence
Amended and Restated Bylaws
−Removed: Employment Separation Agreement, effective as of September 21, 2024, between the Registrant and Vittal Vasista
−Removed: Consulting Agreement, effective as of September 16, 2024, between the Registrant and Vittal Vasista
+Added: Collaboration and License Agreement dated January 14, 2025 between the Registrant and Nippon Shinyaku Co., Ltd.
Certification of the Chief Executive Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002
1 unchanged sentence
Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C.
−Removed: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 formatted in Inline XBRL (eXtensible Business Reporting Language):
+Added: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 formatted in Inline XBRL (eXtensible Business Reporting Language):
(i) Consolidated Balance Sheets
−Removed: (ii) Consolidated Statements of Operations and Comprehensive Loss
+Added: (ii) Consolidated Statements of Operations and Comprehensive Income (Loss)
(iii) Consolidated Statements of Stockholders’ Equity
1 unchanged sentence
(v) Notes to Consolidated Financial Statements
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 formatted in Inline XBRL (included in Exhibit 101)
−Removed: * Management contract or compensatory plan or arrangement.
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 formatted in Inline XBRL (included in Exhibit 101)
+Added: Portions of this exhibit have been omitted.
The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of REGENXBIO Inc.
2 unchanged sentences
REGENXBIO Inc.
−Removed: November 6, 2024
/s/ Curran Simpson
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 6, 2024
/s/ Mitchell Chan
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.